Hwail Pharm Co Ltd
KOSDAQ:061250
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Hwail Pharm Co Ltd
Cash Equivalents
Hwail Pharm Co Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
H
|
Hwail Pharm Co Ltd
KOSDAQ:061250
|
Cash Equivalents
₩58.6B
|
CAGR 3-Years
9%
|
CAGR 5-Years
11%
|
CAGR 10-Years
31%
|
|
|
Yuhan Corp
KRX:000100
|
Cash Equivalents
₩348.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
0%
|
CAGR 10-Years
5%
|
|
|
SK Biopharmaceuticals Co Ltd
KRX:326030
|
Cash Equivalents
₩307.8B
|
CAGR 3-Years
44%
|
CAGR 5-Years
39%
|
CAGR 10-Years
N/A
|
|
|
Hanmi Pharm Co Ltd
KRX:128940
|
Cash Equivalents
₩108.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
-2%
|
|
|
S
|
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
|
Cash Equivalents
₩10B
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-12%
|
|
|
C
|
Caregen Co Ltd
KOSDAQ:214370
|
Cash Equivalents
₩8.8B
|
CAGR 3-Years
20%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Hwail Pharm Co Ltd
Glance View
HWAIL PHARMACEUTICAL Co., Ltd. engages in the manufacture and sale of pharmaceutical products. The company is headquartered in Hwaseong, Gyeonggi-Do and currently employs 149 full-time employees. The company went IPO on 2002-04-18. The firm produces aceclofenac, lornoxicam, triflusal, dicloalphenazone, gallamine triethyl iodide, acemetacin, levosulpiride, alibendol, erdostein, talniflumate, topiramate, phloroglucin, oxatomide and others used as expectorants, cough remedies, antispasmodics, analgesics, anti-inflammatories and others under the brand name EDST, TRPR, LVSP, ACCL and others. The company also provides finished formulations, including injection products such as ceftazidime, cefoperazone, cefotaxime, cefaclor, cefatrizine, cefroxadine and others. The firm distributes its products within domestic market and to overseas markets.
See Also
What is Hwail Pharm Co Ltd's Cash Equivalents?
Cash Equivalents
58.6B
KRW
Based on the financial report for Dec 31, 2025, Hwail Pharm Co Ltd's Cash Equivalents amounts to 58.6B KRW.
What is Hwail Pharm Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
31%
Over the last year, the Cash Equivalents growth was 8%. The average annual Cash Equivalents growth rates for Hwail Pharm Co Ltd have been 9% over the past three years , 11% over the past five years , and 31% over the past ten years .
